UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioblastoma
Glioma
This is an open-label phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of the drug TNG908 in patients with MTAP-deleted advanced or metastatic solid tumors.
Conditions
Glioma
Glioblastoma
The purpose of this prospective, self-controlled study is to evaluate the safety and
effectiveness of using focused ultrasound in adults with glioblastoma to increase temporarily the permeability of the blood-brain barrier, allowing increased passage of circulating free DNA for sampling and analysis.
Conditions
Glioma
Astrocytoma
Glioblastoma
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Summary
This phase II clinical trial will evaluate the efficacy and side effects of larotrectinib in treating patients with previously untreated TRK fusion solid tumors (including central nervous system (CNS) tumors) and relapsed TRK fusion acute leukemia.
Conditions
Glioma
This is a randomized, double-blind, placebo-controlled international phase III study in participants with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy extends overall survival and progression-free survival.
Conditions
Glioma
Glioblastoma
This is a phase I/II trial that aims to to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the blood-brain barrier increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.
Conditions
Glioblastoma
Summary
This is a prospective, randomized, placebo-controlled, multi-center study of patients with newly diagnosed glioblastoma to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide given together with locally administered sargramostim plus adjuvant oral temozolomide (Arm A) versus
Conditions
Medulloblastoma
This phase II clinical trial will evaluate the efficacy of reduced craniospinal radiation therapy in combination with chemotherapy for patients with newly diagnosed WNT-driven medulloblastoma.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
Ependymoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
This is a pilot study to develop a liquid biomarker of hypermutation in glioma patients previously treated with the chemotherapy temozolomide.
Conditions
Glioma
Astrocytoma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Chordoma
Schwannoma (grade 1)
Craniopharyngioma
Oligodendroglioma
Meningioma
Pituitary Tumor
This observational study will collect data to better understand our patient population and their behavior around cannabis, as well as clinical outcomes that might be linked to the consumption of cannabis.
Conditions
Glioblastoma
Glioma
This is a multicenter phase III clinical trial comparing the combination of an implanted focused ultrasound device and carboplatin chemotherapy versus the standard-of-care second line chemotherapy with either lomustine or temozolomide.
Conditions
Glioma
Glioblastoma
This is a randomized, double-blind, placebo-controlled study designed to examine the impact of a custom-formulated, high CBD product on measures of anxiety, quality of life, and tumor progression and imaging stability in newly-diagnosed glioblastoma patients.